Abstract

Hypofractionated radiotherapy (HFRT) has emerged as a promising and cost-effective approach for the management of breast cancer, particularly in early-stage cases. This treatment modality delivers higher doses of radiation over fewer sessions, reducing overall treatment time while maintaining therapeutic efficacy. Recent clinical trials and meta-analyses have demonstrated comparable outcomes in local control and survival rates when compared to conventional fractionation schedules. Additionally, HFRT has been associated with fewer patient visits, which can significantly reduce healthcare costs and improve patient convenience. This paper reviews the current evidence supporting the use of Hypofractionated radiotherapy in breast cancer treatment, highlighting its advantages, potential side effects, and considerations for clinical practice. By examining the economic implications and patient outcomes, we aim to underscore the value of HFRT as a viable option in breast cancer management, ultimately contributing to more efficient healthcare delivery and improved quality of life for patients.